Stefania Borsari, MD; Riccardo Pampena, MD; Aimilios Lallas, MD; et al.
free access
JAMA Dermatol. 2016;152(10):1093-1098. doi:10.1001/jamadermatol.2016.1188
This study examines the accuracy of reflectance confocal microscopy in diagnosing skin cancer in lesions in relation to where they are located on the body.
Thaís Corsetti Grazziotin, MD, PhD; Ivette Alarcon, MD; Renan Rangel Bonamigo, MD, PhD; et al.
free access
JAMA Dermatol. 2016;152(10):1099-1105. doi:10.1001/jamadermatol.2016.1189
This cross-sectional, retrospective study characterizes reflectance confocal microscopy morphologic patterns of melanomas in multiple primary and familial melanomas.
Tami S. Rowen, MD, MS; Thomas W. Gaither, BS; Mohannad A. Awad, MD; et al.
free access
JAMA Dermatol. 2016;152(10):1106-1113. doi:10.1001/jamadermatol.2016.2154
This cross-sectional study characterizes current pubic hair grooming practices in the United States.
Kasper Fjellhaugen Hjuler, MD; Morten Bøttcher, MD, PhD; Christian Vestergaard, MD, PhD, DMSc; et al.
free access
JAMA Dermatol. 2016;152(10):1114-1121. doi:10.1001/jamadermatol.2016.1984
This study investigates whether modulation of inflammation by treatment with biologic agents is associated with progression of coronary artery disease in patients with severe psoriasis.
An-Wen Chan, MD, DPhil; Kinwah Fung, MSc; Jennifer M. Tran, MD; et al.
free access
JAMA Dermatol. 2016;152(10):1122-1127. doi:10.1001/jamadermatol.2016.2609
Using population-based databases linked to laboratory pathology episodes in Ontario, Canada, this study applies recursive partitioning to derive and validate a claims-based algorithm to identify keratinocyte carcinoma with high sensitivity and specificity.
Veronica J. Shi, MD; Nemanja Rodic, MD, PhD; Scott Gettinger, MD; et al.
free access
has active quiz
JAMA Dermatol. 2016;152(10):1128-1136. doi:10.1001/jamadermatol.2016.2226
This case series characterizes the features of lichenoid mucocutaneous adverse effects seen in patients receiving anti–programmed cell death 1 and anti–programmed cell death ligand 1 treatment.